Cited 0 times in
근치적 절제술이 시행된 대장 및 직장암에서 c-erbB-2의 표현과 임상적 의의
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2021-12-27T17:05:23Z | - |
dc.date.available | 2021-12-27T17:05:23Z | - |
dc.date.issued | 1995-06 | - |
dc.identifier.issn | 0496-6872 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186377 | - |
dc.description.abstract | Overexpression of c-erbB-2 oncoprotein has been shown to correlate with poor prognosis and drug-resistance to the conventional chemotherapy with 5-fluorouracil in breast and gastric cancers. To evaluate the clinical significance of c-erbB-2 overexpreseion in colorectal cancer, immunohistochemical staining was performed with the paraffin-embedded tiasues of 141 colorectal cancer patients with curative surgery. The follow-up duration ranged from 7 to 61 months(median 30 months). Two-year disease- free and overall survival rate of the total patients were 77%, 91%, respectively. The c-erbB-2 positive rate was 24.8%, Even if patients with c-erbB-2 overexpression showed a tendency of poor prognosis than c-erbB-2 negative patients, T-factor and the TNM stage were independent prognostic factors in multivariate analysis. In subset analysis with c-erbB-2 negative patienta, there were no differences in recurrence rate and 2-year disease-free survival rate between pa- tients with chemotherapy and without chemotherapy(20.0% versus 26.1%)(80.0% versus 82.0%). However, in c-erbB-2 positive patients, those subgroup with chemotherapy showed tendencies toward advantages in relapse rate and 2-year disease-free survival rate than those of subgroup without chemotherapy(21.0% versus 50.0%; p=0.09)(76.0% versus 50.0%: p=0.06). Also, there was a tendency of increased time to relapse in patients with chemotherapy comparing to that of the patients without chemotherapy(7.5 months versus l7.0 months; p = 0.09). In stage III, patients with c-erbB-2 overexpression showed increased 2-year disease-free survival rate with chemotherapy as comparing to that of patients without chemotherapy(81.0% versus 29.0%; p= 0.003). Again, this survival benefit was not found in c-erbB-2 negative stage III patients regard- less of chemotherapy. In conclusion, c-erbB-2 overexyression might be a marker of relative drug resistance to 5-FU which will be converted with the high dose treatment of modulation with leucovorin. A prospective randomized trial is warrented to confirm this suggestion and for the clinical applica- tion of c-erbB-2 overexpression. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한암학회 | - |
dc.relation.isPartOf | Journal of the Korean Cancer Association(대한암학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 근치적 절제술이 시행된 대장 및 직장암에서 c-erbB-2의 표현과 임상적 의의 | - |
dc.title.alternative | Expression and significance of c-erbB-2 in radically resected colorectal cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 정현철 | - |
dc.contributor.googleauthor | 라선영 | - |
dc.contributor.googleauthor | 박준오 | - |
dc.contributor.googleauthor | 송승훈 | - |
dc.contributor.googleauthor | 조재용 | - |
dc.contributor.googleauthor | 안중배 | - |
dc.contributor.googleauthor | 이혜란 | - |
dc.contributor.googleauthor | 이종인 | - |
dc.contributor.googleauthor | 유내춘 | - |
dc.contributor.googleauthor | 김주항 | - |
dc.contributor.googleauthor | 노재경 | - |
dc.contributor.googleauthor | 성진실 | - |
dc.contributor.googleauthor | 김귀언 | - |
dc.contributor.googleauthor | 민진식 | - |
dc.contributor.googleauthor | 이경식 | - |
dc.contributor.googleauthor | 김병수 | - |
dc.contributor.googleauthor | 임호영 | - |
dc.contributor.googleauthor | 이기범 | - |
dc.contributor.googleauthor | 최진혁 | - |
dc.contributor.googleauthor | 이경희 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J01813 | - |
dc.subject.keyword | c-erbB-2 | - |
dc.subject.keyword | Colorectal cancer | - |
dc.subject.keyword | Drug-resistance | - |
dc.subject.keyword | 5-fluorourecil and leucovorin | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | 김주항 | - |
dc.contributor.affiliatedAuthor | 노재경 | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 성진실 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.contributor.affiliatedAuthor | 조재용 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 389 | - |
dc.citation.endPage | 402 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Cancer Association (대한암학회지), Vol.27(3) : 389-402, 1995-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.